

Article

Hydroquinone Induces NLRP3-Independent IL-18 Release from ARPE-19 Cells

Niina Bhattarai ^{1,*}, Eveliina Korhonen ^{1,2}, Yashavanthi Mysore ¹, Kai Kaarniranta ^{3,4} and Anu Kauppinen ^{1,*}

¹ School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70210 Kuopio, Finland; eveliina.korhonen@uef.fi (E.K.); yashavanthi.mysore@uef.fi (Y.M.)

² Department of Clinical Chemistry, University of Helsinki and Helsinki University Hospital, 00290 Helsinki, Finland

³ Department of Ophthalmology, Institute of Clinical Medicine, University of Eastern Finland, 70210 Kuopio, Finland; kai.kaarniranta@uef.fi

⁴ Department of Ophthalmology, Kuopio University Hospital, 70210 Kuopio, Finland

* Correspondence: niina.bhattarai@uef.fi (N.B.); anu.kauppinen@uef.fi (A.K.); Tel.: +358-44-983-0424 (N.B.); +358-40-355-3216 (A.K.)

Abstract: Age-related macular degeneration (AMD) is a retinal disease leading to impaired vision. Cigarette smoke increases the risk for developing AMD by causing increased reactive oxygen species (ROS) production and damage in the retinal pigment epithelium (RPE). We have previously shown that the cigarette tar component hydroquinone causes oxidative stress in human RPE cells. In the present study, we investigated the propensity of hydroquinone to induce the secretion of interleukin (IL)-1 β and IL-18. The activation of these cytokines is usually regulated by the Nucleotide-binding domain, Leucine-rich repeat, and Pyrin domain 3 (NLRP3) inflammasome. ARPE-19 cells were exposed to hydroquinone, and cell viability was monitored using the lactate dehydrogenase (LDH) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide salt (MTT) assays. Enzyme-linked immunosorbent assays (ELISAs) were used to measure the levels of proinflammatory cytokines IL-1 β and IL-18 as well as NLRP3, caspase-1, and poly (ADP-ribose) polymerase (PARP). Hydroquinone did not change IL-1 β release but significantly increased the secretion of IL-18. Cytoplasmic NLRP3 levels increased after the hydroquinone treatment of IL-1 α -primed RPE cells, but IL-18 was equally released from primed and nonprimed cells. Hydroquinone reduced the intracellular levels of PARP, which were restored by treatment with the ROS scavenger N-acetyl-cysteine (NAC). NAC concurrently reduced the NLRP3 levels but had no effect on IL-18 release. In contrast, the NADPH oxidase inhibitor ammonium pyrrolidinedithiocarbamate (APDC) reduced the release of IL-18 but had no effect on the NLRP3 levels. Collectively, hydroquinone caused DNA damage seen as reduced intracellular PARP levels and induced NLRP3-independent IL-18 secretion in human RPE cells.

Keywords: hydroquinone; oxidative stress; IL-1 β ; IL-18; NLRP3; RPE cell; PARP; DNA damage; NAC; APDC



Citation: Bhattarai, N.; Korhonen, E.; Mysore, Y.; Kaarniranta, K.; Kauppinen, A. Hydroquinone Induces NLRP3-Independent IL-18 Release from ARPE-19 Cells. *Cells* **2021**, *10*, 1405. <https://doi.org/10.3390/cells10061405>

Academic Editor: Juan Pablo de Rivero Vaccari

Received: 24 April 2021

Accepted: 4 June 2021

Published: 6 June 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Cigarette smoke is a risk factor of age-related macular degeneration (AMD) that induces apoptosis, DNA damage, endoplasmic reticulum (ER) stress, mitochondrial fragmentation, reactive oxygen species (ROS) production and vascular endothelial growth factor (VEGF) expression in retinal pigment epithelial (RPE) cells [1–5]. RPE cells maintain retinal homeostasis and support the functionality of photoreceptor cells, i.e., these cells are essential for good vision [6–8]. AMD can develop either into a dry (85–90%) or wet (10–15%) disease form [6,7]. The late forms of AMD manifest with a geographic atrophy in dry AMD or with an exudative form in wet AMD [7,9,10]. RPE degeneration and inflammation are involved in both disease forms [7,11,12]. RPE cell degeneration

is a typical finding, especially in atrophic AMD, whereas choroidal neovascularization, hemorrhages, and swelling of the retina are hallmarks of wet AMD [7,9,10]. Oxidative stress and nucleotide-binding domain, leucine-rich repeat, and pyrin domain 3 (NLRP3) inflammasome activation are fundamental in the pathogenesis of AMD [5,7,10,12–14].

Hydroquinone, a component included in cigarette smoke, induces oxidative stress but prevents nuclear factor kappa B (NF- κ B) activity and the release of interleukin (IL)-6 and IL-8 cytokines from RPE cells [5,15–17]. Increased ROS production is a known activator of NLRP3 inflammasome, leading to the cleavage and release of IL-1 β with or without concurrent maturation of IL-18 in human RPE cells [14,18]. The NLRP3 receptor is a pattern recognition receptor (PRR) that senses a wide variety of danger signals (pathogen or damage-associated molecular patterns i.e., PAMPs or DAMPs, respectively) [12,19,20]. Along with ROS production, its activation mechanisms include lysosomal destabilization and adenosine triphosphate (ATP) release-associated purinergic receptor X7/P2X purinoceptor 7 (P2X7) activation, resulting in K⁺-efflux and Ca²⁺-influx [13,14,18,21–23]. NLRP3 inflammasome activation requires consecutive priming and activation signals [13,19,24]. The priming signal, typically mediated through a Toll-like receptor (TLR) or a cytokine receptor, leads to the expression of the NLRP3 protein as well as the proforms of IL-1 β and caspase-1 [13,25–27]. Epithelial cells tend to express pro-IL-18 continuously without priming [25,27]. An activation signal induces the assembly of NLRP3 inflammasome complex where procaspase-1 becomes attached to oligomerised NLRP3 via the apoptosis-associated speck-like protein containing a caspase-recruitment domain (ASC). The formation of this complex results in caspase-1 activation and subsequent cleavage of IL-1 β and IL-18 into their mature and secreted forms [12,19,20,28]. IL-1 β is involved in inflammatory diseases but it also possesses angiogenic properties [29–31]. IL-18 is a pleiotropic cytokine with distinct effects in different AMD models [32,33]. In mice, it has been observed to be protective against tuberculosis but harmful in combatting *Ehrlichia* infection [34,35].

In this study, we investigated the propensity of hydroquinone to activate NLRP3 inflammasome signaling in human RPE cells since we have previously shown that hydroquinone can induce ROS production in ARPE-19 cells, and oxidative stress is one of the best-known mechanisms of NLRP3 inflammasome activation [14,15,18]. Our results show that in addition to DNA damage, hydroquinone induced both NLRP3 inflammasome and IL-1 α priming-independent secretion of IL-18 in human ARPE-19 cells.

2. Materials and Methods

2.1. Cell Culture and Treatments

Experiments were performed using ARPE-19 cells (ATCC) that were cultured in DMEM/F12 (1:1) medium (Life Technologies, Paisley, UK) with added 10% fetal bovine serum (GE Healthcare Life Sciences, South Logan, UT, USA), penicillin 100 U/mL, streptomycin 100 μ g/mL (Pen Strep, Life Technologies, Grand Island, NY, USA), and L-glutamine 2 mM (Life Technologies, Paisley, UK). The experiments were conducted in the same medium without serum supplement, and L-glutamine was added separately in each independent experiment just prior to the IL-1 α -priming. Hydroquinone was dissolved in the medium before each experiment.

In the experiments, cells were seeded onto 12-well plates (Costar, Corning Inc., Kennebunk, ME, USA) at the density of 200,000 cells per well and incubated for three days at +37 °C under 5% CO₂. The cells were first washed once using serum-free medium and then primed using recombinant human IL-1 α (4 ng/mL, R&D Systems, Minneapolis, MN, USA) for 24 h at +37 °C and 5% CO₂. Thereafter, the cells were washed once again with medium and exposed to hydroquinone (HQ, 10 μ M to 500 μ M; Sigma-Aldrich, Saint Louis, MO, USA) for 18 h at +37 °C and 5% CO₂. After the treatments, medium samples were collected and centrifuged at 381 \times g and +4 °C for 10 min (Biofuge Fresco Heraeus Instruments, Newport Pagnell, UK). Cells were either used directly for a viability assay or collected and lysed for other analyses. Optimal hydroquinone concentrations were probed by exposing cells to 10–500 μ M hydroquinone, and cell viability and the secretion of mature IL-1 β and IL-18

were determined. Two hydroquinone concentrations, 10 μM and 200 μM , were selected for the subsequent NLRP3 assays using only 200 μM for ATP and caspase-1 measurements. Caspase-1 inhibitor (casp.-1 inhib.; 20 μM in DMSO 0.22% *v/v*, Ac-YVAD-cmk, Sigma, St. Louis, MO, USA) was added 1 h before hydroquinone exposure when the role of caspase-1 in IL-18 release was investigated. Hydroquinone (200 μM) was also tested on unprimed cells. In experiments of NLRP3 silencing, ARPE-19 cells were seeded onto 12-well plates at the density of 150,000 cells per well and incubated for 24 h at +37 °C and 5% CO_2 . Cells were washed once with DMEM/F12 medium without serum and antibiotics, and 500 μL of the same medium was added into each well. Cells were transfected by adding lipofectamine (lipofectamine RNAiMAX/lipofectamine 2000, Invitrogen by Thermo Life Technologies Corp., Carlsbad, CA, USA) with NLRP3 siRNA (siNLRP3 10 pmol; NLRP3 Silencer select predesigned siRNA, id:s41556, Ambion, Austin, TX, USA) diluted in Opti-MEM medium (Thermo Fisher Scientific, Grand Island, NY, USA) for 24 h at +37 °C and 5% CO_2 . Negative siRNA (Silencer select Negative control #1 siRNA, Ambion, Austin, TX, USA) and transfection reagent (Tr. reagent; Opti-MEM with lipofectamine) without siRNAs served as controls. After transfection, cells were washed, primed with IL-1 α , and exposed to 200 μM hydroquinone, as described above. The effects of siNLRP3 transfection on the release of IL-18 and lactate dehydrogenase (LDH) were determined.

When determining the effects of antioxidants, cells were primed with IL-1 α for 24 h at +37 °C and 5% CO_2 , washed, and exposed to the NADPH oxidase inhibitor ammonium pyrrolidinedithiocarbamate (APDC, 2 μM ; Sigma-Aldrich, St. Louis, MO, USA) for 5 min, or to the ROS scavenger N-acetyl-cysteine (NAC, 5 mM; Sigma-Aldrich, St. Louis, MO, USA) for 1 h as in our previous investigation of hydroquinone-mediated ROS production [15]. Thereafter, 200 μM hydroquinone was added for an additional 18 h. Untreated and IL-1 α -primed cells served as controls.

2.2. Cell Viability Assays

Before sample collection, the cells were visually observed and photographed using an Axio Vert A1 Zeiss microscope with AxioCam MRm camera and Zen 2011 program (Carl Zeiss Microscopy GmbH, Jena, Germany). Thereafter, half (500 μL) of the cell culture medium was collected and centrifuged, as described above. LDH release was measured from medium samples immediately after the collection using the CytoTox96[®] Non-Radioactive Cytotoxicity Assay (Promega, Madison, WI, USA) according to the manufacturer's instructions. Absorbance values were measured at a wavelength of 490 nm with a spectrophotometer BioTek, ELx808 and the Gen-5 2.04 program (Instruments Inc., Winooski, VT, USA).

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide salt (MTT; 0.5 mg/mL, Sigma-Aldrich, St. Louis, MO, USA) was added to cells remained on 12-well culture plates in the rest of medium (500 μL) and incubated for 3 h in the dark at +37 °C and 5% CO_2 , as described previously [15]. Absorbance values were measured at the wavelength of 560 nm using the spectrophotometer BioTek, ELx808.

2.3. Enzyme-Linked Immunosorbent Assay

The enzyme-linked immunosorbent assay (ELISA) technique was used to determine the levels of active IL-1 β and IL-18, intra- and extracellular NLRP3, as well as cleaved caspase-1 (p20) and poly (ADP-ribose) polymerase (PARP) levels. IL-1 β , IL-18, NLRP3, and caspase-1 were measured using the IL-1 β BD OptEIA[™] Human ELISA Kit (BD Biosciences, San Diego, CA, USA), the Human IL-18 ELISA kit (Invitrogen by Thermo Fisher Scientific, Vienna, Austria), the Human NACHT, LRR and PYD domains-containing protein 3 (NLRP3/c1orf7/CIAS1/NALP3/PYPAF1) ELISA kit (Cusabio Biotech co., LTD, Wuhan, Hubei Province, China), and the Quantikine ELISA Human caspase-1/ICE immunoassay (R&D systems, McKinley, MN, USA), respectively. Absorbance values were determined at the wavelength of 450 nm with the correction wavelength of 655 nm in a spectrophotometer (Bio-Rad Model 550 with the Microplate Manager 5.2 program, Bio-Rad Laboratories Inc.,

Hercules, CA, USA). DNA damage was determined by measuring the PARP levels with the PARP/Apoptosis Colorimetric Assay Kit (R&D Systems, Minneapolis, MN, USA) and detecting absorbance values at the wavelength of 450 nm using a microplate reader Bio-Rad Model 550.

For the detection of intracellular NLRP3, cells were lysed with 40 μ L of 1 \times lysis buffer (Cell Lysis Buffer 10 \times , Cell Signaling Technology, Leiden, Netherlands) in a tube containing cells from one well of a 12-well plate and incubated on ice for 5 min. Thereafter, the lysates were sonicated (3 \times 10 s) and centrifuged at 16,090 \times g and +4 $^{\circ}$ C for 10 min. Supernatants were moved into clean microtubes and their protein concentrations were measured utilizing a protocol based on the Bradford method [36]. Briefly, the bovine serum albumin fraction V (BSA 1 mg/mL; Roche, Mannheim, Germany) was used to create a standard curve (0.5–3.5 μ g/ μ L). Thereafter, samples were pipetted (0.5–3.5 μ L) into wells of a 96-well plate, Bradford solution (200 μ L) was added to all wells, and absorbance values were measured at the wavelength of 595 nm in a spectrophotometer Bio-Rad Model 550. NLRP3 levels were determined from remaining cell lysate using the ELISA technique with the results normalized to the protein level of the respective sample.

When measuring the levels of cleaved caspase-1, cells were lysed using the RIPA buffer (Thermo Scientific, Rockford, IL, USA), incubated for 5 min on ice, and centrifuged at 16,090 \times g and +4 $^{\circ}$ C for 10 min. The Pierce bicinchoninic acid (BCA) protein Assay Kit (Thermo Scientific, Rockford, IL, USA) was used to measure protein concentrations, and 15 or 25 μ g of protein from each sample was used for the ELISA analysis.

When measuring the PARP levels, cells were lysed according to the manufacturer's protocol, and the Pierce BCA protein assay was used to determine protein levels. Thereafter, 5 μ g of protein from sample was used for the ELISA assay.

2.4. Extracellular ATP

The levels of ATP in culture medium were measured using the CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI, USA) following the manufacturer's instructions. Luminescence values were measured using the BioTek Cytation3 imaging reader with the Gen-5 3.03 program (Instruments Inc., Winooski, VT, USA).

2.5. Statistical Analyses

Results were analyzed using the GraphPad Prism program 7.04 (Graphpad Software, San Diego, CA, USA). Normality was determined using the Shapiro-Wilk and D'Agostino & Pearson normality tests (data not presented). Statistical differences between all groups were determined with the Kruskal-Wallis test, and post hoc comparisons using the Mann-Whitney U-test. Results are shown as mean \pm standard error of mean (SEM) and differences were considered as statistically significant with p -values below 0.05.

3. Results

3.1. Hydroquinone Induces IL-18 Secretion in ARPE-19 Cells

Hydroquinone induces ROS production and cytotoxicity concentration-dependently in human ARPE-19 cells [15–17]. In order to investigate whether hydroquinone could induce the secretion of proinflammatory cytokines, IL-1 β and IL-18, we determined their extracellular levels as well as their correlation with cell viability after an exposure of IL-1 α -primed ARPE-19 cells to different hydroquinone concentrations ranging from 10 μ M to 500 μ M. Low hydroquinone concentrations (10–50 μ M) were well tolerated by RPE cells since LDH release and MTT values remained unchanged when compared to IL-1 α -primed ARPE-19 cells without hydroquinone (Figure 1). LDH release was significantly increased in cells exposed to at least 100 μ M hydroquinone, while metabolic activity was significantly reduced when the hydroquinone concentration was 150 μ M or higher (Figure 1).




Figure 1. The effect of hydroquinone (HQ 10–500 μM ; 18 h) on the cell viability of IL-1 α -primed ARPE-19 cells measured using the LDH (A) and MTT (B) assays. Results have been normalized to the mean of the untreated control group. IL-1 α -treated cells served as a control for hydroquinone exposure in primed cells. Data were combined from three independent experiments with four parallel samples per group. Results are shown as mean \pm SEM. **** $p < 0.0001$, ns—not significant, Mann-Whitney U-test.

Next, we measured the production of proinflammatory cytokines IL-1 β and IL-18 from IL-1 α -primed ARPE-19 cells in response to hydroquinone exposure (Figure 2). Hydroquinone had no additional effect on the IL-1 β release, which remained at the same level as in IL-1 α -treated cells (Figure 2A). Hydroquinone induced significant secretion of IL-18 at the 200 μM and 300 μM concentrations, whereas lower (≤ 150 μM) or higher (500 μM) concentrations had no effect on the IL-18 levels (Figure 2B).




Figure 2. The effect of hydroquinone (HQ 10–500 μM ; 18 h) on the release of IL-1 β (A) and IL-18 (B) from IL-1 α -primed ARPE-19 cells. Data were combined from three independent experiments with four parallel samples per group in each experiment. Results are shown as mean \pm SEM. * $p < 0.05$, *** $p < 0.001$, **** $p < 0.0001$, ns—not significant, Mann-Whitney U-test. [Kruskal-Wallis test, (A) ns $p = 0.903$, (B) *** $p < 0.001$].

3.2. Hydroquinone Increases the Intracellular Level of NLRP3 in IL-1 α -Primed ARPE-19 Cells

We showed previously that the oxidative stress induced either by impaired protein clearance or 4-hydroxynonenal (HNE) exposure promoted NLRP3 inflammasome signaling with caspase-1 activation in RPE cells favoring the secretion of IL-1 β or IL-18, respectively [14,18]. In the present study, we investigated whether hydroquinone promoted NLRP3 inflammasome activation in human ARPE-19 cells. We have also showed that NLRP3 is partially degraded, but also secreted, out of the cells after the activation of

the inflammasome [37,38]. In the present study, IL-1 α alone resulted in 2.8 and 43.9-fold intra- and extracellular NLRP3 levels, respectively, when compared to untreated control cells (Figure 3). Hydroquinone at the 10 μ M concentration had no additional effect on the intra- or extracellular levels of NLRP3 when compared to IL-1 α -treated cells without hydroquinone (Figure 3). In contrast, hydroquinone at the 200 μ M concentration significantly elevated the levels of intracellular NLRP3, while the extracellular levels of NLRP3 remained significantly lower (Figure 3). In conclusion, we did not detect any evidence of the release of NLRP3 at the 200 μ M hydroquinone concentration where the production of IL-18 peaked (Figure 2).




Figure 3. The effect of hydroquinone (HQ 10 μ M, 200 μ M; 18 h) on the levels of NLRP3 in cell lysate (A) and medium (B) samples in IL-1 α -primed ARPE-19 cell cultures. Results (A) were normalized to the total protein level. Absorbance values in (A) were 0.263–0.507 in the control, 0.548–1.516 in the IL-1 α , 0.416–0.862 in the IL-1 α + HQ 10 μ M, and 4.492–9.375 in the IL-1 α + HQ 200 μ M group. NLRP3 concentrations in medium samples (B) were 0.590–2.054 ng/mL in the control, 11.81–161.453 ng/mL in the IL-1 α , 10.345–28.244 ng/mL in the IL-1 α + HQ 10 μ M, and 1.268–6.303 ng/mL in the IL-1 α + HQ 200 μ M group. Data were combined from three independent experiments with two (A) or three (B) parallel samples per group in each experiment. Results are shown as mean \pm SEM. *** $p < 0.001$, **** $p < 0.0001$, ns—not significant, Mann-Whitney U-test.

3.3. Hydroquinone Exposure Does Not Induce Caspase-1 Activation in ARPE-19 Cells

Next, we investigated whether caspase-1 would be activated and contributes to the secretion of IL-18 upon hydroquinone exposure in IL-1 α -primed RPE cells. Similarly to the situation with NLRP3, we previously observed that cleaved caspase-1 is partially released from the cell upon inflammasome activation [37,39]. IL-1 α did not increase the intracellular levels of cleaved caspase-1 (p20) when compared to the untreated control cells (Figure 4A). Hydroquinone reduced the caspase-1 (p20) levels in cell lysate samples of IL-1 α -primed ARPE-19 cells when compared to the primed cells without hydroquinone (Figure 4A). Cleaved caspase-1 was not detected in medium samples of controls or hydroquinone-treated cells. Absorbance values were 0.182–0.197 in the control, 0.193–0.204 in the IL-1 α , and 0.182–0.193 in the 200 μ M hydroquinone group of IL-1 α -primed cells. Caspase-1 inhibitor had no effect on the IL-18 release (Figure 4B). These data suggest that hydroquinone did not activate caspase-1 in human ARPE-19 cells.

3.4. Hydroquinone Does Not Need Priming or NLRP3 Inflammasome Activation to Induce IL-18 Release

We have showed previously that UVB irradiation-induced IL-1 β secretion was NLRP3-dependent, but this was not the case for IL-18 release [39]. Next, we examined whether hydroquinone alone would be capable of inducing the release of IL-18 without IL-1 α -priming. Hydroquinone significantly increased IL-18 secretion but the levels of intracellular NLRP3 remained at the levels of untreated control cells (Figure 5). In order to

confirm the NLRP3-independent IL-18 release, cells were treated with siNLRP3 before the hydroquinone exposure of IL-1 α -primed cells. Specific NLRP3 siRNA did not reduce IL-18 release when compared to hydroquinone with transfection reagent without siNLRP3 in IL-1 α -primed cells (Figure 6). These findings support the data shown above that hydroquinone was able to induce IL-18 secretion from ARPE-19 cells without the activation of NLRP3 inflammasome.




Figure 4. The effect of 200 μ M hydroquinone (HQ; 18 h) on the cleaved caspase-1 (p20) levels detected from cell lysate (A) samples and the effect of caspase-1 inhibitor (casp.-1 inhib.; 20 μ M in DMSO 0.22% *v/v*) on the hydroquinone-induced IL-18 release (B) in IL-1 α -primed ARPE-19 cells. Absorbance values in (A) were 0.225–0.288 in the control, 0.259–0.379 in the IL-1 α , and 0.149–0.161 in the IL-1 α + HQ 200 μ M group. Data were combined from two (A) or one (B) independent experiments with two (A) or four (B) parallel samples per group. Results are shown as mean \pm SEM. * $p < 0.05$, ns—not significant, Mann-Whitney U-test.




Figure 5. The effect of 200 μ M hydroquinone (HQ; 18 h) on the IL-18 secretion (A) and on the intracellular NLRP3 level (B) in unprimed ARPE-19 cells. An untreated control group was used as the control for hydroquinone treatment. IL-18 concentrations in medium samples (A) were 4.552–10.556 pg/mL in the control and 32.132–123.617 pg/mL in the HQ 200 μ M group. Absorbance values in (B) were 0.443–0.563 in the control and 0.345–0.579 in the HQ 200 μ M group. Data were combined from two independent experiments containing four (A) or two (B) parallel samples per group. Results are shown as mean \pm SEM. *** $p < 0.001$, ns—not significant, Mann-Whitney U-test.

3.5. APDC Reduces the Release of IL-18 But Not NLRP3, While NAC Has the Opposite Effect upon Hydroquinone Exposure of IL-1 α -Primed ARPE-19 Cells

We showed previously that both NAC and APDC are able to reduce hydroquinone-induced ROS production in RPE cells [15]. Since it is known that IL-18 release from UVB-treated ARPE-19 cells is ROS-dependent [39], we tested whether antioxidants APDC or NAC would exert any effect on RPE cells exposed to hydroquinone. APDC had no effect on the LDH release, but NAC reduced it when compared to primed RPE cells after hydroquinone exposure without the supplementation with antioxidants (Figure 7).

Microscope observations were in line with the LDH data since APDC-treated cells were damaged, but the NAC-treated cells appeared healthy and viable (Figure 8). APDC reduced the secretion of IL-18 but did not affect the intracellular NLRP3 levels (Figure 7). In contrast, NAC had no effect on the levels of IL-18 in IL-1 α -primed ARPE-19 cells exposed to hydroquinone, but the levels of NLRP3 as a part of the total protein concentration were significantly lower when compared to the respective cells without NAC (Figure 7). These results suggest that the release of IL-18 and the expression of NLRP3 protein are not dependent on each other in the cells' response to hydroquinone exposure.




Figure 6. The effect of siNLRP3 on the hydroquinone-induced (HQ 200 μ M; 18 h) release of IL-18 (A) and LDH (B) in IL-1 α -primed ARPE-19 cells. Transfection reagent without siRNAs (Tr. reag.) was used as a control for the siNLRP3 treatment and negative siRNA (Neg. siRNA) was used to indicate if unspecific reduce of IL-18 release was detected. IL-18 concentrations in (A) were 1.342–8.686 pg/mL in the IL-1 α , 4.267–11.166 pg/mL in the Tr. reag. + IL-1 α + HQ 200 μ M, 10.187–12.171 pg/mL in the neg. siRNA + IL-1 α + HQ 200 μ M, and 6.233–12.171 pg/mL in the siNLRP3 + IL-1 α + HQ 200 μ M group. Data were combined from two independent experiments with four parallel samples per group in each experiment. Results are shown as mean \pm SEM. * $p < 0.05$, *** $p < 0.001$, ns—not significant, Mann-Whitney U-test. [Kruskal-Wallis test, (A) *** $p < 0.001$, (B) *** $p < 0.001$].




Figure 7. The effect of antioxidants (2 μ M APDC, 5 mM NAC) in conjunction with 200 μ M hydroquinone (HQ; 18 h) on the release of LDH (A) and IL-18 (B), and on the intracellular NLRP3 (C) levels in IL-1 α -primed ARPE-19 cells. Data were combined from four (A,B) or two (C) independent experiments containing four (A, B) or two (C) parallel samples per group. IL-18 concentrations in (B) were 0.745–10.597 pg/mL in the IL-1 α , 6.515–83.423 pg/mL in the IL-1 α + HQ 200 μ M, 2.58–26.253 pg/mL in the IL-1 α + APDC + HQ 200 μ M, and 7.721–26.506 pg/mL in the IL-1 α + NAC + HQ 200 μ M group. Absorbance values in (C) were 0.62–0.72 in the control, 2.171–2.824 in the IL-1 α + HQ 200 μ M, 1.816–2.564 in the IL-1 α + APDC + HQ 200 μ M, and 1.266–2.25 in the IL-1 α + NAC + HQ 200 μ M group. Results are presented as mean \pm SEM. * $p < 0.05$, *** $p < 0.001$, **** $p < 0.0001$, ns = not significant, Mann-Whitney U-test.




Figure 8. The effect of 200 μM hydroquinone (HQ; 18 h) on ARPE-19 cells with and without IL-1 α -priming and antioxidants (2 μM APDC, 5 mM NAC). Cells were visualized using the Axio Vert A1 Zeiss microscope with AxioCam MRm camera and Zen 2011 program (Carl Zeiss Microscopy GmbH, Jena, Germany).

3.6. Hydroquinone Increases the Levels of Extracellular ATP

Extracellular ATP is reported to be one potential activator of the NLRP3 inflammasome with the effect mediated through the P2X7 receptor, but it can also serve as a secondary response to NLRP3 activation as well as a stimulant for the antioxidant system in times of oxidative stress [18,23,40]. In order to study the potential role of ATP, we measured the extracellular ATP levels after the IL-1 α -primed cells were exposed to hydroquinone. Hydroquinone increased the extracellular ATP levels concurrently while elevating the intracellular level of NLRP3 and the amount of IL-18 from IL-1 α -primed ARPE-19 cells (Figure 9). IL-1 α treatment reduced the extracellular ATP levels in ARPE-19 cell cultures, whereas hydroquinone at 200 μM concentration significantly increased the extracellular ATP levels in IL-1 α -primed cells (Figure 9).




Figure 9. The effect of hydroquinone (HQ 200 μ M; 18 h) exposure on the levels of extracellular ATP in IL-1 α -primed ARPE-19 cell cultures. Results were normalized to the untreated control group. Data were combined from three independent experiments with four parallel samples per group in each experiment. Results are shown as mean \pm SEM. **** $p < 0.0001$, Mann-Whitney U-test.

3.7. Hydroquinone-Induced Reduction in PARP Levels Reflect DNA Damage in ARPE-19 Cells

DNA damage induces NLRP3 inflammasome activation in human keratinocytes [41]. In order to investigate hydroquinone-induced DNA damage and to estimate the correlation between IL-18 release and DNA damage, we determined intracellular PARP levels after hydroquinone exposure. Hydroquinone significantly reduced the levels of the DNA-repairing PARP protein in ARPE-19 cells irrespective of the presence of IL-1 α (Figure 10). APDC boosted the effect of hydroquinone with the reduction being statistically significant after 30 min exposure. In contrast, NAC treatment increased the PARP levels indicating that it was able to alleviate DNA damage.




Figure 10. The effect of 200 μ M hydroquinone (HQ) on the intracellular PARP level with and without IL-1 α -priming and antioxidants (2 μ M APDC, 5 mM NAC) in ARPE-19 cells. IL-1 α and untreated control group were used as the control for hydroquinone treatment. Data were collected from two independent experiments containing three parallel samples per group. Results are shown as mean \pm SEM. ** $p < 0.01$, Mann-Whitney U-test.

4. Discussion

AMD is a consequence of RPE cell degeneration that causes photoreceptor cell death and impaired vision [7]. Oxidative stress, a major factor in the pathogenesis of both dry and wet AMD, is a potent activator of the NLRP3 inflammasome in RPE cells [7,12–14,18].

Hydroquinone is a genotoxic and cytotoxic compound that induces ROS production in RPE cells [15–17,42–44]. However, hydroquinone is sensitive to any kind of variation in experimental conditions, such as changes in diluent or medium supplements, which can influence the concentration needed to evoke cytotoxicity [16,17,43,45]. In the present study, signs of cellular membrane rupturing and reduced metabolic activity were evident in IL-1 α -primed human RPE cells when the hydroquinone concentrations were greater than 100 μ M and 150 μ M, respectively. In our previous experiments with ARPE-19 cells without priming, the corresponding hydroquinone concentrations were 125 μ M and 200 μ M [15]. Thus, our data suggest that if ARPE-19 cells are exposed to the proinflammatory IL-1 α cytokine, this makes them more sensitive to the adverse effects of hydroquinone. This finding is in line with the observation that treatment with an IL-1 receptor antagonist reduced hydroquinone-induced apoptosis in keratinocytes by preventing IL-1 α activity [46].

NLRP3 inflammasome activation with subsequent caspase-1 activation is known to result in the cleavage of pro-IL-1 β and pro-IL-18 into their mature and secreted forms [12,19,20,28]. However, NLRP3 inflammasome activation does not always lead to the secretion of both cytokines [33,39,47]. The accumulation of Alu RNA has been shown to induce IL-18 but not IL-1 β release from RPE cells [33]. The outcome in ARPE-19 cells, especially of IL-18 production, appears to be highly context-dependent. HNE induced the secretion of both cytokines but impaired protein clearance favored IL-1 β secretion with undetectable IL-18 levels [14,47]. Upon exposure to UVB, the same cell cultures produced both cytokines but only IL-1 β was NLRP3 inflammasome-dependent [39]. The present study revealed one more difference i.e., hydroquinone induced IL-18 secretion but had no effect on the production of IL-1 β in IL-1 α -primed ARPE-19 cells. The propensity of hydroquinone to promote IL-18 production has also been observed in a mouse model of contact hypersensitivity [48], which supports the concept that the regulation of IL-18 release strongly depends on the activation signal and may not be as strictly inflammasome-dependent as is the case for IL-1 β .

In our previous study, where UVB induced an NLRP3 inflammasome-independent release of IL-18, we observed that it was ROS that were responsible for the release of the cytokine [39]. We wished to examine another DNA-damaging factor and, therefore, we studied hydroquinone. We observed that APDC, but not NAC, reduced IL-18 secretion after the cells were exposed to hydroquinone. We previously showed that both the NADPH oxidase inhibitor APDC and the ROS scavenger NAC can reduce ROS production induced by hydroquinone in RPE cells [15]. The present data suggest that NADPH oxidase could contribute to the IL-18 production evoked by hydroquinone exposure. However, since NAC treatment exerted no response in RPE cells, APDC probably prevented IL-18 release by some other mechanism and not by inhibiting NADPH oxidase-mediated ROS production.

Extracellular ATP can protect cells from DNA damage caused by chemical exposure; it mediates this effect by activating P2X7 receptors, leading to NADPH oxidase-mediated activation of caspase-4 and 5 [42,44,49,50]. In human intestinal endothelial cells, caspase-4 has been shown to increase mature form of IL-18 in response to an exposure to enteric pathogens [51]. Our results are in line with the concept that the ATP-induced NADPH oxidase mediated caspase-4 or 5 activation could contribute to the production of IL-18, since along with increased IL-18 production, hydroquinone resulted in significant ATP release from RPE cells. In addition, the ability of ATP release to alleviate DNA damage would be compatible with this concept since hydroquinone reduced the PARP levels in RPE cells. PARP participates in the DNA damage repair response and induces poly (ADP-ribose) (PAR) production-related DNA repair [52]. Hydroquinone has been shown to induce DNA damage in human hepatoma HepG2 and TK6 lymphoblastoid cells [42,53,54]. In the latter cells, the extent of the DNA damage correlated with immediately reduced PARP levels as well as with increased PAR production [42].

In this study, we investigated the potential of hydroquinone exposure to induce NLRP3 inflammasome activation in ARPE-19 cells. Hydroquinone induced DNA damage and promoted IL-18 secretion, which was independent from the NLRP3 inflammasome. Since IL-

18 has been reported to reduce DNA damage in UVB-irradiated mouse keratinocytes [55,56], the present results do not exclude the probability that the release of both ATP and IL-18 in response to hydroquinone exposure would be attempted by the human RPE cells to alleviate hydroquinone-induced DNA damage. That proposal will need to be examined in further studies.

5. Conclusions

Hydroquinone induced DNA damage and promoted an NLRP3-independent IL-18 release from RPE cells. NADPH oxidase contributed to IL-18 release but the detailed mechanism still needs clarification.

Author Contributions: Conceptualization, A.K.; methodology, A.K., N.B. and E.K.; validation, A.K. and N.B.; formal analysis, N.B.; investigation, N.B.; resources, A.K.; data curation, A.K. and N.B.; writing—original draft preparation, A.K. and N.B.; writing—review and editing, A.K., N.B., E.K., Y.M. and K.K.; visualization, A.K. and N.B.; supervision, A.K.; project administration, A.K.; funding acquisition, A.K., K.K. and N.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Academy of Finland (297267, 307341, 328443, 296840 and 333302), the Emil Aaltonen Foundation, the Päivikki and Sakari Sohlberg Foundation, the Kuopio University Hospital (5503743), the Finnish Eye Foundation, The Sigrid Juselius Foundation, Sokeain Ystävät ry, and Silmä- ja Kudospankissaatiö. The APC was funded by the Academy of Finland (328443).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available on request from the corresponding authors.

Acknowledgments: We warmly acknowledge laboratory technician Anne Seppänen for her valuable support in the laboratory work and Res. Dir. Emeritus Antero Salminen for his valuable collaboration, discussions, and critical review of the manuscript, and Ewen MacDonald for the language revision.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analysis or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Velilla, S.; García-Medina, J.J.; García-Layana, A.; Dolz-Marco, R.; Pons-Vázquez, S.; Pinazo-Durán, M.D.; Gómez-Ulla, F.; Arévalo, J.F.; Díaz-Llopis, M.; Gallego-Pinazo, R. Smoking and Age-Related Macular Degeneration: Review and Update. *J. Ophthalmol.* **2013**, *2013*, 1–11. [[CrossRef](#)] [[PubMed](#)]
2. Khan, J.C.; Thurlby, D.A.; Shahid, H.; Clayton, D.G.; Yates, J.R.W.; Bradley, M.; Moore, A.T.; Bird, A.C. Smoking and Age Related Macular Degeneration: The Number of Pack Years of Cigarette Smoking is a Major Determinant of Risk for both Geographic Atrophy and Choroidal Neovascularisation. *Br. J. Ophthalmol.* **2006**, *90*, 75–80. [[CrossRef](#)]
3. Fujihara, M.; Nagai, N.; Sussan, T.; Biswal, S.; Handa, J. Chronic Cigarette Smoke Causes Oxidative Damage and Apoptosis to Retinal Pigmented Epithelial Cells in Mice. *PLoS ONE* **2008**, *3*, e3119. [[CrossRef](#)] [[PubMed](#)]
4. Huang, C.; Wang, J.J.; Ma, J.H.; Jin, C.; Yu, Q.; Zhang, S.X. Activation of the UPR Protects Against Cigarette Smoke-Induced RPE Apoptosis through Up-Regulation of Nrf2. *J. Biol. Chem.* **2015**, *290*, 5367–5380. [[CrossRef](#)] [[PubMed](#)]
5. Bertram, K.M.; Baglolle, C.J.; Phipps, R.P.; Libby, R.T. Molecular Regulation of Cigarette Smoke Induced-Oxidative Stress in Human Retinal Pigment Epithelial Cells: Implications for Age-Related Macular Degeneration. *Am. J. Physiol. Cell Physiol.* **2009**, *297*, 1200–1210. [[CrossRef](#)] [[PubMed](#)]
6. Bhutto, I.; Gerard, L. Understanding Age-Related Macular Degeneration (AMD): Relationships between the Photoreceptor/Retinal Pigment Epithelium/Bruch'smembrane/Choriocapillaris Complex. *Mol. Aspects Med.* **2012**, *33*, 295–317. [[CrossRef](#)] [[PubMed](#)]
7. Kaarniranta, K.; Sinha, D.; Blasiak, J.; Kauppinen, A.; Veréb, Z.; Salminen, A.; Boulton, M.E.; Petrovski, G. Autophagy and Heterophagy Dysregulation Leads to Retinal Pigment Epithelium Dysfunction and Development of Age-Related Macular Degeneration. *Autophagy* **2013**, *9*, 973–984. [[CrossRef](#)]
8. Qin, S.; Rodrigues, G.A. Progress and Perspectives on the Role of RPE Cell Inflammatory Responses in the Development of Age-Related Macular Degeneration. *J. Inflamm. Res.* **2008**, *1*, 49–65. [[CrossRef](#)]

9. Zajac-Pytru, H.M.; Pilecka, A.; Turno-Krecicka, A.; Adamiec-Mroczek, J.; Misiuk-Hojlo, M. The Dry Form of Age-Related Macular Degeneration (AMD): The Current Concepts of Pathogenesis and Prospects for Treatment. *Adv. Clin. Exp. Med.* **2015**, *24*, 1099–1104. [[CrossRef](#)]
10. Gao, J.; Liu, R.T.; Cao, S.; Cui, J.Z.; Wang, A.; To, E.; Matsubara, J.A. NLRP3 Inflammasome: Activation and Regulation in Age-Related Macular Degeneration. *Mediat. Inflamm.* **2015**, *2015*, 1–11. [[CrossRef](#)] [[PubMed](#)]
11. Kauppinen, A.; Kaarniranta, K.; Salminen, A. Potential Role of Myeloid-Derived Suppressor Cells (MDSCs) in Age-Related Macular Degeneration (AMD). *Front. Immunol.* **2020**, *11*, 384. [[CrossRef](#)]
12. Kauppinen, A.; Paterno, J.; Blasiak, J.; Salminen, A.; Kaarniranta, K. Inflammation and its Role in Age-Related Macular Degeneration. *Cell. Mol. Life Sci.* **2016**, *73*, 1765–1786. [[CrossRef](#)]
13. Tseng, W.A.; Thein, T.; Kinnunen, K.; Lashkari, K.; Gregory, M.S.; D'Amore, P.A.; Ksander, B.R. NLRP3 Inflammasome Activation in Retinal Pigment Epithelial Cells by Lysosomal Destabilization: Implications for Age-Related Macular Degeneration. *Investig. Ophthalmol. Vis. Sci.* **2013**, *54*, 110–120. [[CrossRef](#)]
14. Kauppinen, A.; Niskanen, H.; Suuronen, T.; Kinnunen, K.; Salminen, A.; Kaarniranta, K. Oxidative Stress Activates NLRP3 Inflammasomes in ARPE-19 Cells—Implications for Age-Related Degeneration (AMD). *Immunol. Lett.* **2012**, *147*, 29–33. [[CrossRef](#)]
15. Bhattarai, N.; Korhonen, E.; Toppila, M.; Koskela, A.; Kaarniranta, K.; Mysore, Y.; Kauppinen, A. Resvega Alleviates Hydroquinone-Induced Oxidative Stress in ARPE-19 Cells. *Int. J. Mol. Sci.* **2020**, *21*, 2066. [[CrossRef](#)] [[PubMed](#)]
16. Ramirez, C.; Cáceres-del-Carpio, J.; Chu, J.; Chu, J.; Moustafa, M.T.; Chwa, M.; Limb, G.A.; Kuppermann, B.D.; Kenney, M.C. Brimonidine can Prevent in Vitro Hydroquinone Damage on Retinal Pigment Epithelium Cells and Retinal Müller Cells. *J. Ocul. Pharmacol. Ther.* **2016**, *32*, 102–108. [[CrossRef](#)] [[PubMed](#)]
17. Moustafa, M.T.; Ramirez, C.; Schneider, K.; Atilano, S.R.; Limb, G.A.; Kuppermann, B.D.; Kenney, M.C. Protective Effects of Memantine on Hydroquinone-Treated Human Retinal Pigment Epithelium Cells and Human Retinal Müller Cells. *J. Ocul. Pharmacol. Ther.* **2017**, *33*, 610–619. [[CrossRef](#)]
18. Piippo, N.; Korhonen, E.; Hytti, M.; Kinnunen, K.; Kaarniranta, K.; Kauppinen, A. Oxidative Stress is the Principal Contributor to Inflammasome Activation in Retinal Pigment Epithelium Cells with Defunct Proteasomes and Autophagy. *Cell. Physiol. Biochem.* **2018**, *49*, 359–367. [[CrossRef](#)] [[PubMed](#)]
19. McKee, C.M.; Coll, R.C. NLRP3 Inflammasome Priming: A Riddle Wrapped in a Mystery Inside an Enigma. *J. Leukoc. Biol.* **2020**, *108*, 937–952. [[CrossRef](#)]
20. Jha, S.; Ting, J.P.-Y. Inflammasome-Associated Nucleotide-Binding Domain, Leucine-Rich Repeat Proteins and Inflammatory Diseases. *J. Immunol.* **2009**, *183*, 7623–7629. [[CrossRef](#)]
21. Triantafilou, K.; Morga, P.; Hughes, T.; Triantafilou, M. The Complement Membrane Attack Complex Triggers Intracellular Ca²⁺ Fluxes Leading to NLRP3 Inflammasome Activation. *J. Cell Sci.* **2013**, *126*, 2903–2913. [[CrossRef](#)]
22. Di Virgilio, F.; Dal Ben, D.; Sarti, A.C.; Giuliani, A.L.; Falzoni, S. The P2 × 7 Receptor in Infection and Inflammation. *Immunity* **2017**, *47*, 15–31. [[CrossRef](#)] [[PubMed](#)]
23. Amores-Iniesta, J.; Barberà-Cremades, M.; Martínez, C.M.; Pons, J.A.; Revilla-Nuin, B.; Martínez-Alarcón, L.; Di Virgilio, F.; Parrilla, P.; Baroja-Mazo, A.; Pelegrín, P. Extracellular ATP Activates the NLRP3 Inflammasome and is an Early Danger Signal of Skin Allograft Rejection. *Cell Rep.* **2017**, *21*, 3414–3426. [[CrossRef](#)]
24. Sutterwala, F.S.; Haasken, S.; Cassel, S.L. Mechanism of NLRP3 Inflammasome Activation. *Ann. N. Y. Acad. Sci.* **2014**, *1319*, 82–95. [[CrossRef](#)] [[PubMed](#)]
25. Dinarello, C. Interleukin 1 and Interleukin 18 as Mediators of Inflammation and the Aging Process. *Am. J. Clin. Nutr.* **2006**, *83*, 447S–455S. [[CrossRef](#)]
26. Dinarello, C.A.; Novick, D.; Kim, S.; Kaplanski, G. Interleukin-18 and IL-18 Binding Protein. *Front. Immunol.* **2013**, *4*, 289. [[CrossRef](#)]
27. Zhu, Q.; Kannegant, T. Distinct Regulatory Mechanisms Control Proinflammatory Cytokines IL-18 and IL-1β. *J. Immunol.* **2017**, *198*, 4210–4215. [[CrossRef](#)]
28. Yang, Y.; Wang, H.; Kouadir, M.; Song, H.; Shi, F. Recent Advances in the Mechanisms of NLRP3 Inflammasome Activation and its Inhibitors. *Cell Death Dis.* **2019**, *10*, 128–139. [[CrossRef](#)]
29. Wooff, Y.; Man, S.M.; Aggio-Bruce, R.; Natoli, R.; Fernando, N. IL-1 Family Members Mediate Cell Death, Inflammation and Angiogenesis in Retinal Degenerative Diseases. *Front. Immunol.* **2019**, *10*, 1618. [[CrossRef](#)] [[PubMed](#)]
30. Dinarello, C.A. Immunological and Inflammatory Functions of the Interleukin-1 Family. *Annu. Rev. Immunol.* **2009**, *27*, 519–550. [[CrossRef](#)] [[PubMed](#)]
31. Voronov, E.; Shouval, D.S.; Krelin, Y.; Cagnano, E.; Benharroch, D.; Iwakura, Y.; Dinarello, C.A.; Apte, R.N. IL-1 is Required for Tumor Invasiveness and Angiogenesis. *Proc. Natl. Acad. Sci. USA* **2003**, *100*, 2645–2650. [[CrossRef](#)]
32. Doyle, S.L.; Campbell, M.; Ozaki, E.; Salomon, R.G.; Mori, A.; Kenna, P.F.; Farrar, G.J.; Kiang, A.; Humphries, M.M.; Lavelle, E.C.; et al. NLRP3 has a Protective Role in Age-Related Macular Degeneration through the Induction of IL-18 by Drusen Components. *Nat. Med.* **2012**, *18*, 791–798. [[CrossRef](#)]
33. Tarallo, V.; Hirano, Y.; Gelfand, B.; Dridi, S.; Kerur, N.; Kim, Y.; Cho, W.; Kaneko, H.; Fowler, B.; Bogdanovich, S.; et al. DICER1 Loss and Alu RNA Induce Age-Related Macular Degeneration Via the NLRP3 Inflammasome and MyD88. *Cell* **2012**, *149*, 847–859. [[CrossRef](#)] [[PubMed](#)]

34. Ghose, P.; Ali, A.Q.; Fang, R.; Forbes, D.; Ballard, B.; Ismail, N. The Interaction between IL-18 and IL-18R Limits the Magnitude of Protective Immunity and Enhances Pathogenic Responses Following Infection with Intracellular Bacteria. *J. Immunol.* **2011**, *187*, 1333–1346. [[CrossRef](#)]
35. Schneider, B.E.; Korb, D.; Hagens, K.; Koch, M.; Raupach, B.; Enders, J.; Kaufmann, S.H.E.; Mittrücker, H.; Schaible, U.E. A Role for IL-18 in Protective Immunity Against Mycobacterium Tuberculosis. *Eur. J. Immunol.* **2010**, *40*, 396–405. [[CrossRef](#)]
36. Bradford, M.M. A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding. *Anal. Biochem.* **1976**, *72*, 248–254. [[CrossRef](#)]
37. Bhattarai, N.; Piippo, N.; Ranta-Aho, S.; Mysore, Y.; Kaarniranta, K.; Kauppinen, A. Effects of Resvega on Inflammasome Activation in Conjunction with Dysfunctional Intracellular Clearance in Retinal Pigment Epithelial (RPE) Cells. *Antioxidants* **2021**, *10*, 67. [[CrossRef](#)] [[PubMed](#)]
38. Piippo, N.; Korhonen, E.; Hytti, M.; Skottman, H.; Kinnunen, K.; Josifovska, N.; Petrovski, G.; Kaarniranta, K.; Kauppinen, A. Hsp90 Inhibition as a Means to Inhibit Activation of the NLRP3 Inflammasome. *Sci. Rep.* **2018**, *8*, 6720–6729. [[CrossRef](#)] [[PubMed](#)]
39. Korhonen, E.; Piippo, N.; Hytti, M.; Hyttinen, J.M.T.; Kaarniranta, K.; Kauppinen, A. Only IL-1 β Release is Inflammasome-Dependent upon Ultraviolet B Irradiation although IL-18 is also Secreted. *FASEB J.* **2020**, *34*, 6437–6448. [[CrossRef](#)]
40. Satoh, E.; Tsukimoto, M.; Kojima, S. Involvement of P2Y Receptors in the Protective Effect of ATP Towards the Cell Damage in HaCaT Cells Exposed to H₂O₂. *J. Toxicol. Sci.* **2011**, *36*, 741–750. [[CrossRef](#)]
41. Hasegawa, T.; Nakashima, M.; Suzuki, Y. Nuclear DNA Damage-Triggered NLRP3 Inflammasome Activation Promotes UVB-Induced Inflammatory Responses in Human Keratinocytes. *Biochem. Biophys. Res. Commun.* **2016**, *477*, 329–335. [[CrossRef](#)]
42. Ling, X.X.; Liu, J.X.; Yun, L.; Du, Y.J.; Chen, S.Q.; Chen, J.L.; Tang, H.W.; Liu, L.H. Poly(ADP-Ribosyl)ation of Apoptosis Antagonizing Transcription Factor Involved in Hydroquinone-Induced DNA Damage Response. *Biomed. Environ. Sci.* **2016**, *29*, 80–84. [[CrossRef](#)]
43. Cho, J.Y. Suppressive Effect of Hydroquinone, a Benzene Metabolite, on in Vitro Inflammatory Responses Mediated by Macrophages, Monocytes, and Lymphocytes. *Mediat. Inflamm.* **2008**, *2008*, 1–11. [[CrossRef](#)]
44. Bolton, J.L.; Trush, M.A.; Penning, T.M.; Dryhurst, G.; Monks, T.J. Role of Quinones in Toxicology. *Chem. Res. Toxicol.* **2000**, *13*, 135–160. [[CrossRef](#)] [[PubMed](#)]
45. Lee, J.; Yang, E.; Kim, I. Hydroquinone-Induced Apoptosis of Human Lymphocytes through Caspase 9/3 Pathway. *Mol. Biol. Rep.* **2012**, *39*, 6737–6743. [[CrossRef](#)] [[PubMed](#)]
46. Lee, H.; Cheong, K.A.; Kim, J.; Kim, N.; Noh, M.; Lee, A. IL-1 Receptor Antagonist Reduced Chemical-Induced Keratinocyte Apoptosis through Antagonism to IL-1 α /IL-1 β . *Biomol. Ther.* **2018**, *26*, 417–423. [[CrossRef](#)]
47. Piippo, N.; Korkmaz, A.; Hytti, M.; Kinnunen, K.; Salminen, A.; Atalay, M.; Kaarniranta, K.; Kauppinen, A. Decline in Cellular Clearance Systems Induces Inflammasome Signaling in Human ARPE-19 Cells. *Biochim. Biophys. Acta* **2014**, *1843*, 3038–3046. [[CrossRef](#)] [[PubMed](#)]
48. Bando, K.; Tanaka, Y.; Kuroishi, T.; Sasaki, K.; Takano-Yamamoto, T.; Sugawara, S.; Endo, Y. Mouse Model of Hydroquinone Hypersensitivity Via Innate and Acquired Immunity and its Promotion by Combined Reagents. *J. Investig. Dermatol.* **2017**, *137*, 1082–1093. [[CrossRef](#)]
49. Aho, J.; Helenius, M.; Vattulainen-Collanus, S.; Alastalo, T.; Koskenvuo, J. Extracellular ATP Protects Endothelial Cells Against DNA Damage. *Purinergic Signal.* **2016**, *12*, 575–581. [[CrossRef](#)] [[PubMed](#)]
50. Roberts, J.S.; Yilmaz, Ö. Dangerous Liaisons: Caspase-11 and Reactive Oxygen Species Crosstalk in Pathogen Elimination. *Int. J. Mol. Sci.* **2015**, *16*, 23337–23354. [[CrossRef](#)]
51. Knodler, L.; Crowley, S.; Sham, H.; Yang, H.; Wrande, M.; Ma, C.; Ernst, R.; Steele-Mortimer, O.; Celli, J.; Vallance, B. Non-Canonical Inflammasome Activation of Caspase-4/Caspase-11 Mediates Epithelial Defenses Against Enteric Bacterial Pathogens. *Cell Host Microbe* **2014**, *16*, 249–256. [[CrossRef](#)]
52. Sousa, F.G.; Matuo, R.; Soares, D.G.; Escargueil, A.E.; Henriques, J.A.P.; Larsen, A.K.; Saffi, J. PARPs and the DNA Damage Response. *Carcinogenesis* **2012**, *33*, 1433–1440. [[CrossRef](#)]
53. Liu, J.; Yuan, Q.; Ling, X.; Tan, Q.; Liang, H.; Chen, J.; Lin, L.; Xiao, Y.; Chen, W.; Liu, L.; et al. PARP-1 may be Involved in Hydroquinone-Induced Apoptosis by Poly ADP-Ribosylation of ZO-2. *Mol. Med. Rep.* **2017**, *16*, 8076–8084. [[CrossRef](#)]
54. Luo, L.; Jiang, L.; Geng, C.; Cao, J.; Zhong, L. Hydroquinone-Induced Genotoxicity and Oxidative DNA Damage in HepG2 Cells. *Chem. Biol. Interact.* **2008**, *173*, 1–8. [[CrossRef](#)] [[PubMed](#)]
55. Schwarz, T.; Schwarz, A. DNA Repair and Cytokine Responses. *J. Investig. Dermatol. Symp. Proc.* **2009**, *14*, 63–66. [[CrossRef](#)] [[PubMed](#)]
56. Schwarz, A.; Maeda, A.; Ständer, S.; van Steeg, H.; Schwarz, T. IL-18 Reduces Ultraviolet Radiation-Induced DNA Damage and Thereby Affects Photoimmunosuppression. *J. Immunol.* **2006**, *176*, 2896–2901. [[CrossRef](#)] [[PubMed](#)]